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Evidence-Based Case Conference (4) Helping people with schizophrenia to quit smoking 
 
Toshi A. Furukawa 
Kyoto University Graduate School of Medicine / School of Public Health 
 
Clinical Case 
Patient: 38-year-old man 
Present illness: The patient developed schizophrenia in his mid-20s when he was 
working as a shop assistant in a busy supermarket. He was increasingly unable to 
concentrate, felt that he was laughed at by his colleagues and customers, and started 
seeing a psychiatrist after he heard voices and felt he was no longer able to control his 
body by his will. He has had two brief hospitalisations in the interim, had several 
temporary jobs but not been able to keep a steady job over a year. For the past two years 
he has been attending the day care centre four days a week. 
Present status:. He has been a heavy smoker since his 20s, smoking at least one packet 
a day. The consumption usually increased when he does not have a job and remained 
two packets a day for the past two years. Recently there was some discussion around 
the harms of cigarette smoking at the day care centre and he wonders if there is any 
medication that may help him in stopping cigarettes. He says he has tried several times 
on his own in vain. His present mental status mainly consists of negative symptoms 
(blunted affect, social withdrawal and anhedonia) and some residual positive symptoms 
(vague and distant auditory hallucinations). He does not suffer from substance-related 
disorders other than tobacco use disorder. 
 
FORMULATE YOUR CLINICAL QUESTION 
Patients:  Patients with schizophrenia who smoke 
Intervention:  Pharmacological intervention 
Comparison:  Placebo 
Outcomes:  Continued abstinence from smoking 
 
LITERATURE SEARCH 
Ideally clinical decisions should be based on the totality of evidence and not on 
individual trials. You therefore start looking for a study that tries to look at the total 
body of evidence, a systematic review. 
Being uncertain if treatments shown to help people to quit smoking in general may not 
  
have the same effectiveness and may have different adverse effects for people with 
schizophrenia, you decide to look for a systematic review that specifically looked at 
interventions for smoking cessation among people with schizophrenia. Visiting PubMed 
and searching its MeSH database, you notice that “smoking cessation” is a MeSH term 
and you enter “smoking cessation”[mesh] and “schizophrenia”[mesh] in Clinical Queries. 
The second under the heading “Systematic Reviews” is a Cochrane review on this very 
topic. Tsoi DT, Porwal M & Webster AC (2013) Interventions for smoking cessation and 
reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews, 
2, CD007253. 
 
CRITICAL APPRAISAL OF A SYSTEMATIC REVIEW 
In order to appraise the totality of evidence we will follow the new Users’ Guide recently 
published in JAMA[1]. 
First judgment: Evaluate the credibility of the methods of systematic review 
Did the review explicitly address a sensible clinical question? 
YES. The clinical question of this review may be summarised as: 
P: patients with schizophrenia or schizoaffective disorder 
I: pharmacological or non-pharmacological intervention aiming at smoking cessation 
or reduction 
C: another intervention, placebo or usual care 
O: smoking cessation. 
Our original clinical question PICO is not exactly the same as this review’s PICO but 
we expect that the latter covers the former, and would like to read on. 
  
Was the search for relevant studies exhaustive? 
YES. The review authors searched the Cochrane Tobacco Addiction Group Specialized 
Register and several electronic databases, in addition to clinical trials registers and 
handsearching. The search terms in the appendix looks comprehensive. 
 
Were selection and assessments of studies reproducible? 
YES/NO. The selection and assessments were done by two or more independent 




Did the review present results that are ready for clinical application? 
YES. The results were reported separately for individual interventions; only results 
for bupropion were summarisable in a clinically meaningful way. They are provided 
in forest plots as RRs and in the summary of findings table as NNTs. 
 
Did the review address confidence in estimates of effect? 
YES. The review authors provided enough information for the readers to judge 
confidence in study results, such as risks of bias for individual trials and 
heterogeneity among the included trials. 
 
Second judgment: Rate the confidence in the effect estimates 
How serious is the risk of bias in the body of evidence? 
NOT SERIOUS. Cochrane reviews assess and present risks of bias of each included 
studies in the domains of random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, and selective reporting. The five studies included for the comparison 
bupropion vs placebo were judged to be mostly at either low or unclear risk of bias. 
 
Are the results consistent across studies? 
YES. The forest plot for the comparison bupropion vs placebo presents little 
variability from study to study, and the I2 statistic was estimated to be 0%. 
 
How precise are the results? 
NOT VERY PRECISE. The pooled RR of bupropion over placebo (with or without 
nicotine patch) for abstinence at 6-month follow-up was 2.78 (1.02 to 7.58). While this 
estimate is “statistically significant,” the lower end of its 95% confidence interval is 
close to unity (no difference between the two arms) and would indicate no clinically 
meaningful benefit of bupropion over placebo. The estimate is therefore not precise. 
 
Do the results directly apply to my patient? 
YES. The average age of the included patients was in the 40s, they had been 
diagnosed as suffering from schizophrenia or schizoaffective disorder according to 
DSM-IV and had expressed interest in quitting. There appears to be no strong reason 




Is there concern about reporting bias? 
PROBABLY NO. The number of the included studies (5 out of 7 relevant trials) is too 
small to statistically examine the possibility of publication bias. The literature search 
appears very comprehensive but in the current practice of the medical literature 




WHAT WILL YOU DO WITH YOUR PATIENT? 
While the point estimate of bupropion over placebo in bringing about abstinence from 
smoking at 6-month follow-up appears impressive (RR=2.78), the lower limit of its 
confidence interval is only marginally above 1.0. Moreover, given the very low success 
rate in the placebo group (approximately 5%), this RR would translate into NNT of 12 (3 
to 1000), using the following formulae. 
 NNT = 1 / Risk difference 
 Risk difference = Control event rate * RR – Control event rate 
where Control event rate = 5%, RR = 2.78 (and its upper or lower confidence limits). 
On the other hand, this review noted that there were no significant differences in 
schizophrenic or depressive symptoms between bupropion and placebo. In the included 
trials, as reported in the literature for bupropion in general, the drug was associated 
with insomnia, restlessness and dry mouth among others. You conclude that there is 
moderate quality evidence that bupropion would bring an important yet small benefit 
for people with schizophrenia who smoke but who would like to quit smoking. After 
some discussion with you, your patient decided to give bupropion a try. 
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